Delcath Systems

Technology to target organs and regions of the body with dosages of therapeutics not feasible through systemic routes such as oral (pill) or intravenous delivery. Whole-body drug exposure is minimized to protect the patient from harmful systemic side-effects. Can be used with a diversity of drugs, including chemotherapeutics, biologics, antivirals, and antibiotics, and is adaptable to a variety of applications such as for cancer, hepatitis, infection, and diseased organs.

Currently being investigated in phase III and phase II trials for the treatment of primary liver cancer and metastatic cancer in the liver including, melanoma (ocular and cutaneous), adenocarcinoma (such as colorectal), and neuroendocrine tumors.

Delcath Systems
Rockefeller Center
600 Fifth Avenue
New York, NY 10020
212-489-2100
info@delcath.com

www.liverperfusion.com
www.livercancertrials.com
www.regionalperfusion.com
www.delcath.com

Nasdaq Symbol - DCTH

less